Stockwatch: Innovative Therapies 2020 – A Commercial Odyssey
Few Life Science Companies Increased Revenues In 2020, But Some Suffered More than Most
Executive Summary
The development and commercialization of cell and gene therapies during a pandemic, with regulators and payers demanding more data on effect duration and safety, has resulted in headwinds. Added to manufacturing and clinical trial recruitment issues, investors’ patience has been strained.